Sun Pharmaceutical Industries Limited along with one of its wholly owned subsidiaries announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid® (lenalidomide capsules) in the US.
- Read more about Sun Pharma Announces Settlement of Patent Litigation for Generic Revlimid (lenalidomide) in US
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/sun-pharma-announces-settlement-of-patent-litigation-for-generic-revlimid-lenalidomide-in-us
No comments:
Post a Comment